AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancerBusiness Wire • 05/21/25
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthmaBusiness Wire • 05/19/25
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's LymphomaAccesswire • 05/14/25
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025Business Wire • 05/13/25
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'The Guardian • 05/12/25
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%Zacks Investment Research • 05/09/25
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trialBusiness Wire • 05/09/25
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patientsProactive Investors • 05/09/25
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chiefProactive Investors • 05/07/25
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 04/29/25
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million PenaltyBenzinga • 04/29/25
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key DrugsZacks Investment Research • 04/29/25
AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study FlopsInvestors Business Daily • 04/29/25
AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectorsReuters • 04/29/25